



CDPHP Medicare Advantage Part B Step Therapy Drug List

Step therapy is when a member is required to try a preferred medication before a non-preferred medication is approved. **Step therapy requirements will apply to new starts of non-preferred medications and as part of the Part B benefit only.**

Class	Non-preferred Drug(s)*	Preferred Drug(s)
<i>Bone resorption inhibitors</i>	Prolia (denosumab) J0897	Zoledronic acid J3489
<i>Biosimilars</i>	Rituxan (rituximab) J9312 Rituxan Hycela (rituximab and hyaluronidase) J9311	Ruxience (rituximab-pvvr) Q5119 Truxima (rituximab-abbs) Q5115 Riabni (rituximab-arrx) Q5123
<i>Biosimilars</i>	Herceptin (trastuzumab) J9355 Herceptin Hylecta (trastuzumab and hyaluronidase) J9356	Trazimera (trastuzumab-qyyp) Q5116 Ogivri (trastuzumab-dkst) Q5114 Herzuma (trastuzumab-pkrb) Q5113 Kanjinti (trastuzumab-anns) Q5117 Ontruzant (trastuzumab-dttb) Q5112
<i>Biosimilars</i>	Avastin (bevacizumab) J9035	Alymsys (bevacizumab-maly) C9142 Mvasi (bevacizumab-awwb) Q5107 Zirabev (bevacizumab-bvzr) Q5118 Vegzelma (bevacizumab-adcd) Q5129
<i>Multiple Sclerosis</i>	Lemtrada (alemtuzumab) J0202	Tysabri (natalizumab) J2323

**This list of drugs may change throughout the year.*